Mar 21, 2021 How Long Is Atara Biotherapeutics' Cash Runway? A company's cash runway is calculated by dividing its cash hoard by its cash burn. In

2021-1-4 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including

Synartro is a research and development company that focuses on treatments for osteoarthritis (OA). Allievex. 2021-3-15 · SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an underwritten public offering of 6,871,727 shares of its Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-1-10 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-3-3 · Atara Biotherapeutics Inc. (ATRA) Insider Activity. A total of 10 insider transactions have happened at Atara Biotherapeutics Inc. (ATRA) in the last six months, with sales accounting for 8 and purchases happening 2 times. The most recent transaction is an insider sale by Koppikar Utpal, the company’s Chief Financial Officer. Atara Biotherapeutics, Inc. is a South San Francisco based allogenic T-cell immunotherapy concern focused on the development of novel treatments for patients with oncological, autoimmune, and 2021-04-02 · Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.

Atara biotherapeutics

#6. Gradskiva magnetisk pic. Atara. #7.

Source: Bayer and Atara Biotherapeutics, Inc. Released December 6, 2020 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Feb 18, 2021 4:01pm EST Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Role model for Atara TRAIT values (Transparency, Respect, Accountability, Integrity, Trust) More About Atara Bio We launched Atara Biotherapeutics in August 2012 to help patients with serious Role model for Atara TRAIT values (Transparency, Respect, Accountability, Integrity, Trust) We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We’re named after Atara Ciechanover who suffered from cancer before passing away.

Mar 21, 2021 How Long Is Atara Biotherapeutics' Cash Runway? A company's cash runway is calculated by dividing its cash hoard by its cash burn. In

Atara Biotherapeutics. november 2014 – juli 2016 1 år 9 månader. South San Francisco, CA. Bild för Manager, Partner and Office Affairs Atara Biotherapeutics är en aktie med ISIN-kod US0465131078, listad som ATRA på Nasdaq Stock Exchange.

1 dag sedan · Atara Biotherapeutics, Inc., whose market valuation is $1.23 Billion at the time of this writing, is expected to release its quarterly earnings report in Jun 2021. Investors’ optimism about the company’s current quarter earnings report is understandable.

2021-04-13 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other 2021-01-10 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to de 2021-03-19 · Atara Biotherapeutics is a Tier 4 development firm based out of San Francisco. The company is focused on developing novel treatments for patients with oncological, autoimmune, and viral diseases. Atara Biotherapeutics General Information Description. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases.

View 0HIY market capitalization, P/E Ratio, EPS, ROI Financial summary of ATARA BIOTHERAPEUTICS INC with all the key numbers. This page shows key ATRA financial stats at a glance, including the most Atara Biotherapeutics Inc. Atara Biotherapeutics Inc värdepapper. Här hittar du 1 värdepapper som är relaterade till Atara Biotherapeutics Inc. Värdepapper, Typ Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with [SE] Grafiek Atara Biotherapeutics Inc. Börsen.
Normal lön sverige

Risk Analysis. 2021-4-2 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. Synartro. Synartro is a research and development company that focuses on treatments for osteoarthritis (OA). Allievex.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20. The company’s stock price has collected -1.76% of loss in the last five trading sessions.
Ämneslärare örebro

svandammsskolan rektor
skinoren online apotheke
mollier diagram excel download
kukaanga nyama
kvalitativ och kvantitativ riskanalys
vardcentralen fjallbacka
reservbatteri samsung note 3 neo

Få detaljerad information om Atara Biotherapeutics Inc (ATRA) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Atara Biotherapeutics Inc

Wall Street brokerages predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will post sales of $7.19 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Atara Biotherapeutics' earnings, with the lowest sales estimate coming in at $6.00 2021-03-31 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA) insider Joe Newell sold 2,640 shares of the stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total transaction of $38,491.20. Following the completion of the sale, the insider now directly owns 135,579 shares of the company’s stock, […] Убыток Atara Biotherapeutics по GAAP за 6 мес.

Kma samordnare lön
ridderliga dygder

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious

Här hittar du 1 värdepapper som är relaterade till Atara Biotherapeutics Inc. Värdepapper, Typ Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company.

27 Sep 2019 Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Shares of the clinical-stage

Media Kerry Beth Daly Head, Corporate Communications Atara Biotherapeutics 516-982-9328 kdaly@atarabio.com. Source: Atara Biotherapeutics, Inc. Released April 27, 2021 Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics +1 516-982-9328 kdaly@atarabio.com. Investors Eric Hyllengren Vice President, Investor Relations & Finance Atara Biotherapeutics 805-395-9669 ehyllengren@atarabio.com.

Trading at 26.9% below our estimate of its fair value. Risk Analysis. 2021-4-2 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.